Phase II, 2nd Line Melanoma - RAND Monotherapy
Public ClinicalTrials.gov record NCT00612664. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks
Study identification
- NCT ID
- NCT00612664
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 158 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2008 (Type not available)
- Primary completion
- Oct 2009 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- Oct 12, 2015
2008 – 2009
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic & Research Institute | Los Angeles | California | 90025 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06520 | — |
| Oncology Specialists, S.C. | Park Ridge | Illinois | 60068 | — |
| Indiana University Melvin And Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Harry & Jeanette Weinberg Cancer Inst At Franklin Square | Baltimore | Maryland | 21237 | — |
| Dana-Farber Cancer Inst | Boston | Massachusetts | 02115 | — |
| Mem Sloan-Ket Can Ctr | New York | New York | 10021 | — |
| Blumenthal Cancer Center, Carolinas Medical Center | Charlotte | North Carolina | 28204 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| University Of Texas | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00612664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 12, 2015 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00612664 live on ClinicalTrials.gov.